Torramadé J R, Cienfuegos J A, Hernández J L, Pardo F, Benito C, González J, Balén E, de Villa V
Department of General Surgery, Clinica Universitaria de Navarra, School of Medicine, University of Navarra, Spain.
Eur J Surg. 1993 Jun-Jul;159(6-7):323-7.
To evaluate the safety and usefulness of systems for obtaining central venous access.
Prospective open study.
Clinica Universitaria de Navarra, Spain.
218 consecutive patients who required long term venous access either for chemotherapy or for total parenteral nutrition, and who had no evidence of infection, a platelet count of over 40 x 10(9)/l, and a life expectancy of three months or more, had 234 devices inserted.
Insertion of either a silicone rubber (Port-A-Cath) or a polyurethane (Implantofix) catheter into the cephalic, jugular or subclavian vein, leaving the tip in the superior vena cava.
Between February 1985 and December 1990, 234 devices were implanted in 218 patients aged from 0.9 to 78 years. The median (range) length of time that the catheters functioned was 277 (7-1887) days. The overall incidence of complications was 0.09/100 days inserted, and the complication rates for infection and thrombosis were 0.02 and 0.03/100 days, respectively. Thirty two devices were removed because of complications, and 19 because the treatment had finished. Five of the 218 patients (2%) were lost to follow up.
These devices have a long working life, and a low rate of complications, and are of great value to patients who require long term or cyclical intravenous treatment.
评估获得中心静脉通路系统的安全性和实用性。
前瞻性开放性研究。
西班牙纳瓦拉大学诊所。
218例连续患者,他们因化疗或全胃肠外营养需要长期静脉通路,且无感染证据,血小板计数超过40×10⁹/L,预期寿命3个月或更长,共植入234套装置。
将硅橡胶(Port-A-Cath)或聚氨酯(Implantofix)导管插入头静脉、颈静脉或锁骨下静脉,使导管尖端位于上腔静脉。
1985年2月至1990年12月,218例年龄在0.9至78岁的患者共植入234套装置。导管发挥功能的中位(范围)时间为277(7 - 1887)天。并发症的总发生率为0.09/100天,感染和血栓形成的并发症发生率分别为0.02和0.03/100天。32套装置因并发症被拔除,19套因治疗结束被拔除。218例患者中有5例(2%)失访。
这些装置使用寿命长,并发症发生率低,对需要长期或周期性静脉治疗的患者具有重要价值。